183 related articles for article (PubMed ID: 36804527)
21. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
[TBL] [Abstract][Full Text] [Related]
22. A framework for chemical safety assessment incorporating new approach methodologies within REACH.
Ball N; Bars R; Botham PA; Cuciureanu A; Cronin MTD; Doe JE; Dudzina T; Gant TW; Leist M; van Ravenzwaay B
Arch Toxicol; 2022 Mar; 96(3):743-766. PubMed ID: 35103819
[TBL] [Abstract][Full Text] [Related]
23. Do nanomedicines require novel safety assessments to ensure their safety for long-term human use?
Hoet P; Legiest B; Geys J; Nemery B
Drug Saf; 2009; 32(8):625-36. PubMed ID: 19591528
[TBL] [Abstract][Full Text] [Related]
24. Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long-term opportunities?
Burden N; Aschberger K; Chaudhry Q; Clift MJD; Fowler P; Johnston H; Landsiedel R; Rowland J; Stone V; Doak SH
Regul Toxicol Pharmacol; 2017 Dec; 91():257-266. PubMed ID: 29069581
[TBL] [Abstract][Full Text] [Related]
25. Revising REACH guidance on information requirements and chemical safety assessment for engineered nanomaterials for aquatic ecotoxicity endpoints: recommendations from the EnvNano project.
Hansen SF; Sørensen SN; Skjolding LM; Hartmann NB; Baun A
Environ Sci Eur; 2017; 29(1):14. PubMed ID: 28337404
[TBL] [Abstract][Full Text] [Related]
26. t⁴ workshop report. Nanotoxicology: "the end of the beginning" - signs on the roadmap to a strategy for assuring the safe application and use of nanomaterials.
Silbergeld EK; Contreras EQ; Hartung T; Hirsch C; Hogberg H; Jachak AC; Jordan W; Landsiedel R; Morris J; Patri A; Pounds JG; de Vizcaya Ruiz A; Shvedova A; Tanguay R; Tatarazako N; van Vliet E; Walker NJ; Wiesner M; Wilcox N; Zurlo J
ALTEX; 2011; 28(3):236-41. PubMed ID: 21993959
[TBL] [Abstract][Full Text] [Related]
27. Sameness: The regulatory crux with nanomaterial identity and grouping schemes for hazard assessment.
Walser T; Studer C
Regul Toxicol Pharmacol; 2015 Aug; 72(3):569-71. PubMed ID: 26049104
[TBL] [Abstract][Full Text] [Related]
28. [Management and safety assessment of nanomaterials in food: status and prospects].
Li ZQ; Zheng WW; Liu Y; Zhou Y; He GS; Zheng YX; Qu WD
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Oct; 52(10):1082-1088. PubMed ID: 30392333
[TBL] [Abstract][Full Text] [Related]
29. Enhancing the use of exposure science across EU chemical policies as part of the European Exposure Science Strategy 2020-2030.
Bruinen de Bruin Y; Franco A; Ahrens A; Morris A; Verhagen H; Kephalopoulos S; Dulio V; Slobodnik J; Sijm DTHM; Vermeire T; Ito T; Takaki K; De Mello J; Bessems J; Zare Jeddi M; Tanarro Gozalo C; Pollard K; McCourt J; Fantke P
J Expo Sci Environ Epidemiol; 2022 Jul; 32(4):513-525. PubMed ID: 34697409
[TBL] [Abstract][Full Text] [Related]
30. Toward toxicity testing of nanomaterials in the 21st century: a paradigm for moving forward.
Lai DY
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2012; 4(1):1-15. PubMed ID: 21965171
[TBL] [Abstract][Full Text] [Related]
31. Risk Governance of Emerging Technologies Demonstrated in Terms of its Applicability to Nanomaterials.
Isigonis P; Afantitis A; Antunes D; Bartonova A; Beitollahi A; Bohmer N; Bouman E; Chaudhry Q; Cimpan MR; Cimpan E; Doak S; Dupin D; Fedrigo D; Fessard V; Gromelski M; Gutleb AC; Halappanavar S; Hoet P; Jeliazkova N; Jomini S; Lindner S; Linkov I; Longhin EM; Lynch I; Malsch I; Marcomini A; Mariussen E; de la Fuente JM; Melagraki G; Murphy F; Neaves M; Packroff R; Pfuhler S; Puzyn T; Rahman Q; Pran ER; Semenzin E; Serchi T; Steinbach C; Trump B; Vrček IV; Warheit D; Wiesner MR; Willighagen E; Dusinska M
Small; 2020 Sep; 16(36):e2003303. PubMed ID: 32700469
[TBL] [Abstract][Full Text] [Related]
32. Developing Integrated Approaches for Testing and Assessment (IATAs) in order to support nanomaterial safety.
Powell LG; Gillies S; Fernandes TF; Murphy F; Giubilato E; Cazzagon V; Hristozov D; Pizzol L; Blosi M; Costa AL; Prina-Mello A; Bouwmeester H; Sarimveis H; Janer G; Stone V
Nanotoxicology; 2022 May; 16(4):484-499. PubMed ID: 35913849
[TBL] [Abstract][Full Text] [Related]
33. Toxicity testing of nanomaterials.
Schrand AM; Dai L; Schlager JJ; Hussain SM
Adv Exp Med Biol; 2012; 745():58-75. PubMed ID: 22437813
[TBL] [Abstract][Full Text] [Related]
34. In silico analysis of nanomaterials hazard and risk.
Cohen Y; Rallo R; Liu R; Liu HH
Acc Chem Res; 2013 Mar; 46(3):802-12. PubMed ID: 23138971
[TBL] [Abstract][Full Text] [Related]
35. TRAAC framework to improve regulatory acceptance and wider usability of tools and methods for safe innovation and sustainability of manufactured nanomaterials.
Shandilya N; Barreau MS; Suarez-Merino B; Porcari A; Pimponi D; Jensen KA; Fransman W; Franken R
NanoImpact; 2023 Apr; 30():100461. PubMed ID: 37040858
[TBL] [Abstract][Full Text] [Related]
36. A weight of evidence approach for hazard screening of engineered nanomaterials.
Hristozov DR; Zabeo A; Foran C; Isigonis P; Critto A; Marcomini A; Linkov I
Nanotoxicology; 2014 Feb; 8(1):72-87. PubMed ID: 23153309
[TBL] [Abstract][Full Text] [Related]
37. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
38. A European nano-registry as a reliable database for quantitative risk assessment of nanomaterials? A comparison of national approaches.
Pavlicek A; Part F; Rose G; Praetorius A; Miernicki M; Gazsó A; Huber-Humer M
NanoImpact; 2021 Jan; 21():100276. PubMed ID: 35559789
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxicity screening of 23 engineered nanomaterials using a test matrix of ten cell lines and three different assays.
Kroll A; Dierker C; Rommel C; Hahn D; Wohlleben W; Schulze-Isfort C; Göbbert C; Voetz M; Hardinghaus F; Schnekenburger J
Part Fibre Toxicol; 2011 Feb; 8():9. PubMed ID: 21345205
[TBL] [Abstract][Full Text] [Related]
40. Approaches to Develop Alternative Testing Strategies to Inform Human Health Risk Assessment of Nanomaterials.
Stone V; Johnston HJ; Balharry D; Gernand JM; Gulumian M
Risk Anal; 2016 Aug; 36(8):1538-50. PubMed ID: 27285586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
